Lead Product(s): NeoTCR-T cell
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vida Ventures
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 10, 2020
PACT Pharma Series C proceeds wili expand the scope of its clinical plan to investigate NeoTCR-T cell products targeting multiple neoantigens for a spectrum of solid tumor types.